Dapsone and Adverse event - a phase IV clinical study of FDA data

Summary:

Adverse event is reported as a side effect among people who take Dapsone (dapsone), especially for people who are female, 60+ old, also take Clopidogrel, and have Systemic lupus erythematosus.

The phase IV clinical study analyzes which people have Adverse event when taking Dapsone. It is created by eHealthMe based on reports of 11,499 people who have side effects when taking Dapsone from the FDA, and is updated regularly.

What is Dapsone?

Dapsone has active ingredients of dapsone. It is often used in dermatitis herpetiformis. eHealthMe is studying from 11,732 Dapsone users. Check the latest studies of Dapsone.

What is Adverse event?

Adverse event is found to be associated with 1,690 drugs and 1,662 conditions by eHealthMe. Check the latest studies of Adverse event.

On Jul, 07, 2026

11,499 people reported to have side effects when taking Dapsone.
Among them, 36 people (0.31%) have Adverse event.

Among these 36 people:

What is the gender of people who have Adverse event when taking Dapsone? *

female: 70.37 %
male: 29.63 %

What is the age of people who have Adverse event when taking Dapsone? *

What are other drugs people take besides Dapsone? *

Benlysta: 12 people, 33.33%
Clopidogrel: 12 people, 33.33%
Vitamin D: 7 people, 19.44%
Methotrexate: 7 people, 19.44%
Prednisolone: 6 people, 16.67%
Carvedilol: 6 people, 16.67%
Simvastatin: 6 people, 16.67%
Hydroxychloroquine Sulfate: 6 people, 16.67%
Benadryl: 5 people, 13.89%
Campath: 5 people, 13.89%

What are other side effects people have besides Adverse event? *

Drug Ineffective: 17 people, 47.22%
Urinary Tract Infection: 14 people, 38.89%
Pain: 14 people, 38.89%
Malaise (a feeling of general discomfort or uneasiness): 13 people, 36.11%
Rashes (redness): 13 people, 36.11%
Muscle Rigidity (muscle stiffness): 12 people, 33.33%
Rickets (softening of bones): 12 people, 33.33%
Laboratory Test Abnormal: 12 people, 33.33%
Movement Disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness): 12 people, 33.33%
Joint Pain: 12 people, 33.33%

What are the existing conditions these people have? *

Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 12 people, 33.33%
T-Cell Prolymphocytic Leukaemia (a aggressive type of t cell cancer): 5 people, 13.89%
Xanthogranuloma (self-limiting tumour with self healing): 2 people, 5.56%
Linear Iga Disease (a rare, idiopathic or drug-induced autoimmune blistering disease of skin): 1 person, 2.78%
Acne (skin problems that cause pimples): 1 person, 2.78%
Asthma: 1 person, 2.78%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 2.78%
Constipation: 1 person, 2.78%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 2.78%
Drug Hypersensitivity: 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Dapsone and have Adverse event?

- Check whether Adverse event is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dapsone:

Dapsone (11,732 reports)

Adverse event treatments and more:

Adverse event (100,133 reports)

Browse all side effects of Dapsone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Adverse event:

Adverse event (1,690 drugs)

Browse all the conditions that are associated with Adverse event:

Adverse event (1,662 conditions)

Related publications that referenced our studies

Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .
Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dapsone (the active ingredients of Dapsone) and Dapsone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.